135 related articles for article (PubMed ID: 36867101)
21. Synthesis of phosphoramidate prodrugs: ProTide approach.
Serpi M; Madela K; Pertusati F; Slusarczyk M
Curr Protoc Nucleic Acid Chem; 2013 Jun; Chapter 15():15.5.1-15.5.15. PubMed ID: 23775807
[TBL] [Abstract][Full Text] [Related]
22. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
23. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.
Hoang NT; Kadonosono T; Kuchimaru T; Kizaka-Kondoh S
Cancer Sci; 2016 Aug; 107(8):1151-8. PubMed ID: 27270607
[TBL] [Abstract][Full Text] [Related]
25. Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Sugyo A; Tsuji AB; Sudo H; Koizumi M; Ukai Y; Kurosawa G; Kurosawa Y; Saga T; Higashi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274301
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
27. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
28. [Design, synthesis and anti-HBV activity of L-amino acid ester prodrugs of acyclic nucleoside phosphonates].
Fu XZ; Jiang SH; Yang YS; Ji RY
Yao Xue Xue Bao; 2008 May; 43(5):495-503. PubMed ID: 18717337
[TBL] [Abstract][Full Text] [Related]
29. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy.
Zhang Y; Kim WY; Huang L
Biomaterials; 2013 Apr; 34(13):3447-58. PubMed ID: 23380359
[TBL] [Abstract][Full Text] [Related]
30. WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition.
Wang R; Li Y; Gao J; Luan Y
Drug Discov Ther; 2022 Dec; 16(6):286-292. PubMed ID: 36529509
[TBL] [Abstract][Full Text] [Related]
31. Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Miao H; Chen X; Luan Y
Curr Med Chem; 2020; 27(33):5562-5582. PubMed ID: 31419928
[TBL] [Abstract][Full Text] [Related]
32. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z
Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548
[TBL] [Abstract][Full Text] [Related]
34. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.
Tsume Y; Borras Bermejo B; Amidon GL
Pharmaceuticals (Basel); 2014 Jan; 7(2):169-91. PubMed ID: 24473270
[TBL] [Abstract][Full Text] [Related]
35. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
36. β-D-2'-α-F-2'-β-C-Methyl-6-O-substituted 3',5'-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: a structure-activity relationship study.
Du J; Bao D; Chun BK; Jiang Y; Reddy PG; Zhang HR; Ross BS; Bansal S; Bao H; Espiritu C; Lam AM; Murakami E; Niu C; Micolochick Steuer HM; Furman PA; Otto MJ; Sofia MJ
Bioorg Med Chem Lett; 2012 Sep; 22(18):5924-9. PubMed ID: 22892115
[TBL] [Abstract][Full Text] [Related]
37. Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in vivo antitumor effects in PANC-1 pancreatic cancer.
Yoon Y; Lim JW; Kim J; Kim Y; Chun KH
Bioorg Med Chem Lett; 2016 Nov; 26(22):5524-5527. PubMed ID: 27769622
[TBL] [Abstract][Full Text] [Related]
38. Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro.
Wang Y; Li Y; Lu J; Qi H; Cheng I; Zhang H
Molecules; 2018 May; 23(5):. PubMed ID: 29772747
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
40. Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer.
Bulanadi JC; Xue A; Gong X; Bean PA; Julovi SM; de Campo L; Smith RC; Moghaddam MJ
Chempluschem; 2020 Jun; 85(6):1283-1291. PubMed ID: 32543086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
